RMD.AX ResMed Inc. Earnings Preview April 30, 2026

ResMed Inc. (RMD.AX) will report its latest earnings on April 30, 2026. The healthcare medical devices company trades at A$31.78 with a market cap of A$46.30 billion. Investors are watching closely as ResMed navigates the competitive sleep and respiratory care markets. The company’s recent performance shows strong profitability metrics, with a net profit margin of 27.5% and solid cash generation. Meyka AI rates RMD.AX with a grade of B+, reflecting balanced fundamentals and growth potential. This earnings preview examines what to expect from the report and key metrics investors should monitor.

ResMed Earnings Preview: What to Watch

ResMed’s earnings report will focus on two core business segments: Sleep and Respiratory Care, plus Software as a Service. The company has demonstrated consistent profitability with strong operational efficiency. Recent financial data shows net income per share of A$1.43, indicating solid earnings power. Investors should monitor revenue growth trends, particularly in cloud-based software solutions which represent high-margin business opportunities.

Revenue Growth Expectations

ResMed reported 9.8% revenue growth in the most recent period, showing steady expansion. The company’s revenue per share stands at A$3.72, reflecting a diversified customer base across 140 countries. Analysts will examine whether growth momentum continues or faces headwinds from market saturation or competitive pressures. The software segment typically carries higher margins and faster growth rates than hardware.

Profitability and Margins

The company maintains impressive gross profit margins of 60.7%, demonstrating pricing power and operational efficiency. Operating profit margins reached 33.9%, well above many healthcare peers. Net profit margins of 27.5% show strong bottom-line performance. Investors should watch whether these margins expand or contract due to cost pressures or product mix changes.

Cash Flow Generation

ResMed generated strong operating cash flow per share of A$1.32 and free cash flow per share of A$1.23. The company’s cash conversion cycle of 185.5 days reflects typical healthcare inventory and receivables patterns. Strong cash generation supports dividends and potential acquisitions in the fragmented healthcare software market.

Financial Health and Balance Sheet Strength

ResMed maintains a fortress balance sheet with conservative leverage and ample liquidity. The company’s current ratio of 3.06 indicates strong short-term financial flexibility. Debt-to-equity ratio of just 0.16 shows minimal financial risk. These metrics provide confidence in the company’s ability to invest in growth and weather economic uncertainty.

Liquidity and Working Capital

Cash per share of A$0.98 provides operational cushion for the company. Working capital of A$2.57 billion demonstrates substantial resources for operations and strategic initiatives. The company’s quick ratio of 2.32 shows it can meet short-term obligations without relying on inventory sales. This strong liquidity position supports dividend payments and potential share buybacks.

Debt Management

Interest coverage ratio of 191.5x indicates ResMed can easily service its debt obligations. Net debt to EBITDA of negative 0.20 shows the company has more cash than debt. Long-term debt represents only 8.1% of total capitalization. This conservative capital structure provides flexibility for strategic acquisitions or increased shareholder returns.

Return on Capital

Return on equity of 24.9% demonstrates efficient use of shareholder capital. Return on assets of 17.5% shows strong asset productivity. Return on invested capital of 19.9% exceeds the cost of capital, creating shareholder value. These metrics suggest management executes well on capital allocation decisions.

Growth Trajectory and Analyst Expectations

ResMed’s earnings growth has accelerated significantly, with net income growing 37.2% in the most recent period. EPS growth of 37.6% outpaced revenue growth of 9.8%, showing operating leverage. This divergence suggests margin expansion and improved operational efficiency. Investors should assess whether this growth trajectory is sustainable or represents a temporary peak.

Historical Growth Patterns

Three-year revenue growth per share reached 43.2%, while five-year growth hit 71.2%. Operating cash flow per share grew 396.6% over three years, indicating improving cash generation. Net income per share grew 78.9% over three years, demonstrating strong earnings power development. These trends suggest ResMed is successfully scaling its business model.

Forward Growth Outlook

Analysts expect ResMed to maintain mid-to-high single-digit revenue growth. Software segment growth should outpace hardware, driving overall margin expansion. The aging population and rising prevalence of sleep apnea support long-term demand. Cloud-based software adoption accelerates, creating recurring revenue streams with higher margins.

Valuation Context

The stock trades at a PE ratio of 22.22, slightly above historical averages. Price-to-sales ratio of 6.13 reflects premium valuation for a healthcare company. PEG ratio of 24.22 suggests the stock may be fairly valued given growth rates. Investors should assess whether current valuation leaves room for upside surprises.

Key Metrics and Meyka AI Grade Analysis

Meyka AI rates RMD.AX with a grade of B+, reflecting balanced fundamentals and solid growth prospects. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating suggests ResMed offers reasonable value for healthcare investors seeking exposure to medical devices and software. The company scores particularly well on profitability and cash generation metrics.

Profitability Metrics

ResMed’s net profit margin of 27.5% ranks in the top tier for healthcare companies. Operating margin of 33.9% demonstrates operational excellence and pricing power. Gross margin of 60.7% provides cushion for cost increases and competitive pressures. These metrics support the B+ grade and suggest earnings quality is high.

Growth and Efficiency

The company’s three-year EPS growth of 78.9% significantly exceeds sector averages. Asset turnover of 0.64x is reasonable for a capital-intensive healthcare company. Receivables turnover of 5.17x shows efficient collections and strong customer relationships. Inventory turnover of 2.31x reflects typical healthcare product cycles.

Risk Factors

Debt-to-equity of 0.16 is conservative but leaves room for strategic leverage. PE ratio of 22.22 prices in significant growth expectations. Regulatory changes in healthcare could impact margins. Competition from larger medical device companies poses ongoing challenges. The B+ grade reflects these balanced risks and opportunities.

Final Thoughts

ResMed Inc. enters its April 30 earnings report with strong financial fundamentals and accelerating growth momentum. The company’s 37.2% net income growth, fortress balance sheet, and 27.5% net margins demonstrate operational excellence. With a B+ Meyka AI grade, ResMed offers balanced risk-reward for healthcare investors. Key metrics to watch include software segment growth, margin sustainability, and cash flow generation. The stock’s 22.22 PE ratio reflects growth expectations, leaving limited room for disappointment. Investors should focus on guidance for the coming quarters and management commentary on competitive dynamics and cloud adoption trends.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.